Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.
Repligen Expands Into Cell Therapy
The acquisition aims to capitalize on the rapidly expanding cell therapy sector. Industry commercial revenues are forecast to surge by over 20% annually through 2030.
BioLife’s biopreservation products, notably CryoStor, complement Repligen’s existing bioprocessing technologies.
Currently, BioLife’s portfolio supports 18 commercialized therapies and a majority of United States cell-based clinical trials.
